Latest Views & News

Scancell – Cancer Research Drops SCIB 2: Excuses are like A*seholes, we've all got 'em no-one cares!

By Nigel Somerville, the Deputy Sheriff of AIM | Wednesday 3 February 2021

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.

There was bad news this morning from AIM-listed cancer-buster Scancell (SCLP): Cancer Research UK has pulled out of a funding deal to put Scancell’s second SCIB product through Phase I/II trials.

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £5.99 per month for all articles, the Bearcast, and our seven year archive.

Filed under:

Subscribe to our newsletter

Daily digest of our latest stories.

Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was